食管胃交接部腺癌患者T细胞表达与病理参数及淋巴结转移的关系研究  

Expression of T cell in adenocarcinoma of the esophagogastric junction and their pathological parameters and lymph node metastasis

作　　者：李东辉[1] 李杰[1] 王艳伟[1] LI Dong-hui;LI Jie;WANG Yan-wei(Department of Sythesis Surgery,Handan First Hospital,Handan 056004,China)

机构地区：[1]邯郸市第一医院纺医院区综合外科,河北邯郸056004

出　　处：《中国实验诊断学》2022年第3期326-329,共4页Chinese Journal of Laboratory Diagnosis

基　　金：河北省科技厅重点研发计划课题(172777150)。

摘　　要：目的观察T细胞在食管胃交接部腺癌(AEG)组织中的表达特点,探讨其与肿瘤发展、预后的关系。方法收集70例AEG肿瘤组织及50例癌旁正常黏膜组织,应用免疫组化法进行染色,检测CD8、Foxp3的表达水平,对其在TNM分期、淋巴转移、组织分化程度等的分布情况进行观察。结果AEG组的CD8^(+)、Foxp3阳性率均高于对照组;CD8^(+)、Foxp3同时为阳性的患者占41.43%,同为阴性表达占2.86%。CD8^(+)、Foxp3在肿瘤TNM分期Ⅲ期的阳性率均高于Ⅰ-Ⅱ期,且在低分化组织中的阳性率高于中高分化组。CD8^(+)在发生淋巴结转移时的阳性率为55.81%,Foxp3为76.74%。生存期<5年的Foxp3表达阳性率69.81%明显高于≥5年的23.53%。结论CD8^(+)、Foxp3的表达与AEG发生、发展密切相关,且对肿瘤分期、组织学分型具有分辨性。Objective To explore expression of T cell in tissues of adenocarcinoma of the esophagogastric junction(AEG)and analyze their correlation with tumor progression and prognosis.Methods 70AEG tumor tissues and 50paracancer normal mucosa tissues were collected.Using immunohistochemistry evaluating CD8^(+)and Foxp3,and TNM stage,lymphatic metastasis,tissue differentiation were observed.Results The positive rates of CD8^(+)and Foxp3in AEG group were higher than those in control group.Both CD8^(+)and Foxp3were positive in 41.43% of patients,and negative in 2.86%.The positive rate of CD8^(+)and Foxp3in TNM stage ofⅢ were higher than those in the stageⅠ-Ⅱ,and the positive rate in poorly differentiated tissues were higher than those in medium and highly differentiated tissues.The positive rate of CD8^(+)and Foxp3in lymph node metastasis was 55.81%,76.74%.The positive rate of Foxp3expression in patients with survival<5years was 69.81%,significantly higher than that in the patients with survival≥5years 23.53%.Conclusion The expression of CD8^(+)、Foxp3is significantly associated with AEG carcinogenesis and progression.It can distinguish tumor stage and tissue type.

关 键 词：腺癌 食管胃交接部 淋巴转移 T细胞 

分 类 号：R735.1[医药卫生—肿瘤] R735.2[医药卫生—临床医学]